But other current employees are dissatisfied with where the strategy shift has left them.
In January 2023, Pfizer forecast a steep drop in annual revenue, to between $67 billion and $71 billion.
Pfizer's 2023 revenue ultimately came in at $58.5 billion, including $11.22 billion from its Covid vaccine and $1.28 billion from Paxlovid.
Faith in executive leadership also plunged among some workers, according to most of the current and former employees who spoke with CNBC.
Some current workers said that hasn't appeared to change after the town hall on May 2.
Persons:
Albert Bourla, Wall, they're, Bourla, I'm, drugmaker Seagen, Irfan Khan, hasn't, Pfizer, renegotiating, John Thys, Payal Sahni Becher, Becher, Kena, Mike McDermott, Bourla's
Organizations:
Corbis, Getty, Pfizer, Wall, CNBC, Los Angeles Times, Moderna, Centers for Disease Control, U.S ., GSK, Bristol Myers Squibb, Pfizer wasn't, . Biotech, Companies, Biotech, BioNtech, Reuters, Human, View Press, Global, APEC, Summit, Tech, Google
Locations:
U.S, Covid, Eagle Rock , California, Durham , North Carolina, Puurs, Belgium, New York City, Peapack , New Jersey, Kena